NDAORALTABLET
Approved
Nov 2015
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
8
Data completeness
7/8 — Comprehensive
GENVOYA (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) by Gilead Sciences is hiv integrase inhibitors [moa]. Approved for human immunodeficiency virus integrase strand transfer inhibitor [epc]. First approved in 2015.
Drug data last refreshed 2h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
GENVOYA is a fixed-dose combination antiretroviral tablet containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide approved in 2015 for HIV-1 infection. It combines an integrase inhibitor with a pharmacokinetic booster and two nucleoside reverse transcriptase inhibitors. The drug works primarily through cytochrome P450 3A inhibition to enhance and optimize antiretroviral efficacy.
$626MPart D
Peak6.7 years to LOEProduct is at peak commercial maturity with $626M annual spending (148K claims in 2023), indicating stable market presence but approaching patent cliff requiring defensive positioning.
Mechanism of Action
HIV Integrase Inhibitors
Pharmacologic Class:
Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor
Clinical Trials (8)
Analysis of Crushed and Whole Tablet Genvoya
Started Apr 2019
12 enrolled
Healthy Volunteers
Same-Day Treatment With Genvoya vs. EFV/TDF/3TC
Started May 2018
0HIV/AIDS
Switch to Genvoya Followed by HCV Therapy With Epclusa Followed by Simplification of HIV Therapy With Biktarvy in Patients With HIV-HCV Co-Infected Subjects on Opioid Substitution Therapy
Started Feb 2018
25 enrolled
HIV-1-infectionHepatitis C, ChronicMethadone Dependence+6 more
Evaluation of Compliance With Treatment by Genvoya in HIV Post-exposure Prophylaxis
Started Mar 2017
101 enrolled
HIV Risk
Efficacy and Safety of E/C/F/TAF (Genvoya®) in HIV-1/Hepatitis B Co-infected Adults
Started Feb 2014
79 enrolled
HIVHBV
Worked on GENVOYA at Gilead Sciences? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.